$29.94
Insights on Perrigo Company Public Limited Company
Revenue is up for the last 2 quarters, 1.12B → 1.15B (in $), with an average increase of 2.9% per quarter
Netprofit is down for the last 2 quarters, 14.2M → -32.3M (in $), with an average decrease of 327.5% per quarter
In the last 1 year, Catalent, Inc. has given 33.0% return, outperforming this stock by 50.3%
0.37%
Downside
Day's Volatility :0.74%
Upside
0.37%
14.76%
Downside
52 Weeks Volatility :34.93%
Upside
23.66%
Period | Perrigo Company Public Limited Company | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -8.36% | -0.7% | 0.0% |
6 Months | -0.13% | 6.6% | 0.0% |
1 Year | -17.27% | 3.7% | -1.5% |
3 Years | -27.96% | 14.0% | -21.8% |
Market Capitalization | 4.1B |
Book Value | $35.19 |
Dividend Share | 1.092 |
Dividend Yield | 3.65% |
Earnings Per Share (EPS) | -0.03 |
PEG Ratio | 0.96 |
Wall Street Target Price | 40.5 |
Profit Margin | -0.27% |
Operating Margin TTM | 7.94% |
Return On Assets TTM | 1.64% |
Return On Equity TTM | -0.09% |
Revenue TTM | 4.7B |
Revenue Per Share TTM | 34.41 |
Quarterly Revenue Growth YOY | 0.1% |
Gross Profit TTM | 1.5B |
EBITDA | 646.2M |
Diluted Eps TTM | -0.03 |
Quarterly Earnings Growth YOY | -0.64 |
EPS Estimate Current Year | 2.35 |
EPS Estimate Next Year | 2.94 |
EPS Estimate Current Quarter | 0.83 |
EPS Estimate Next Quarter | 0.7 |
What analysts predicted
Upside of 35.27%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 4.7B | ↓ 4.34% |
Net Income | 131.0M | ↑ 9.53% |
Net Profit Margin | 2.77% | ↑ 0.35% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 4.8B | ↑ 2.23% |
Net Income | 146.1M | ↑ 11.53% |
Net Profit Margin | 3.02% | ↑ 0.25% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 5.1B | ↑ 4.67% |
Net Income | -162.6M | ↓ 211.29% |
Net Profit Margin | -3.21% | ↓ 6.23% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 4.1B | ↓ 18.26% |
Net Income | -130.9M | ↓ 19.5% |
Net Profit Margin | -3.16% | ↑ 0.05% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 4.5B | ↑ 7.56% |
Net Income | -130.9M | ↑ 0.0% |
Net Profit Margin | -2.94% | ↑ 0.22% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 4.7B | ↑ 4.58% |
Net Income | -12.7M | ↓ 90.3% |
Net Profit Margin | -0.27% | ↑ 2.67% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.1B | ↓ 1.92% |
Net Income | -52.1M | ↓ 19.72% |
Net Profit Margin | -4.74% | ↑ 1.05% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.2B | ↑ 5.01% |
Net Income | -12.7M | ↓ 75.62% |
Net Profit Margin | -1.1% | ↑ 3.64% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.2B | ↑ 2.29% |
Net Income | -1.1M | ↓ 91.34% |
Net Profit Margin | -0.09% | ↑ 1.01% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.2B | ↑ 0.96% |
Net Income | 8.4M | ↓ 863.64% |
Net Profit Margin | 0.7% | ↑ 0.79% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.1B | ↓ 5.81% |
Net Income | 14.2M | ↑ 69.05% |
Net Profit Margin | 1.26% | ↑ 0.56% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.2B | ↑ 2.95% |
Net Income | -32.3M | ↓ 327.46% |
Net Profit Margin | -2.79% | ↓ 4.05% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 11.0B | ↓ 5.55% |
Total Liabilities | 5.3B | ↓ 2.62% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 11.3B | ↑ 2.9% |
Total Liabilities | 5.5B | ↑ 3.42% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 11.5B | ↑ 1.65% |
Total Liabilities | 5.8B | ↑ 6.11% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 10.4B | ↓ 9.25% |
Total Liabilities | 5.3B | ↓ 9.59% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 11.0B | ↑ 5.67% |
Total Liabilities | 6.2B | ↑ 17.09% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 10.8B | ↓ 1.89% |
Total Liabilities | 6.0B | ↓ 2.17% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 10.7B | ↓ 2.22% |
Total Liabilities | 6.1B | ↑ 0.08% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 11.0B | ↑ 3.18% |
Total Liabilities | 6.2B | ↑ 1.65% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.0B | ↓ 0.57% |
Total Liabilities | 6.1B | ↓ 0.88% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.0B | ↑ 0.09% |
Total Liabilities | 6.1B | ↓ 0.08% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 10.8B | ↓ 1.88% |
Total Liabilities | 6.0B | ↓ 1.57% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 10.8B | ↑ 0.47% |
Total Liabilities | 6.0B | ↑ 0.35% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 593.0M | ↓ 15.15% |
Investing Cash Flow | -126.8M | ↓ 105.42% |
Financing Cash Flow | -571.9M | ↓ 80.97% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 387.8M | ↓ 34.6% |
Investing Cash Flow | -596.1M | ↑ 370.11% |
Financing Cash Flow | 1.8M | ↓ 100.31% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 636.2M | ↑ 64.05% |
Investing Cash Flow | -187.8M | ↓ 68.5% |
Financing Cash Flow | -181.1M | ↓ 10161.11% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 156.3M | ↓ 75.43% |
Investing Cash Flow | 1.3B | ↓ 779.34% |
Financing Cash Flow | -178.7M | ↓ 1.33% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 307.3M | ↑ 96.61% |
Investing Cash Flow | -2.0B | ↓ 253.52% |
Financing Cash Flow | 421.6M | ↓ 335.93% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 59.2M | ↓ 450.3% |
Investing Cash Flow | -20.9M | ↓ 98.94% |
Financing Cash Flow | -43.0M | ↓ 107.69% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 185.9M | ↑ 214.02% |
Investing Cash Flow | -26.0M | ↑ 24.4% |
Financing Cash Flow | -42.5M | ↓ 1.16% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 19.4M | ↓ 89.56% |
Investing Cash Flow | -19.6M | ↓ 24.62% |
Financing Cash Flow | -50.7M | ↑ 19.29% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 52.9M | ↑ 172.68% |
Investing Cash Flow | -4.4M | ↓ 77.55% |
Financing Cash Flow | -48.6M | ↓ 4.14% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 124.5M | ↑ 135.35% |
Investing Cash Flow | -30.7M | ↑ 597.73% |
Financing Cash Flow | -43.3M | ↓ 10.91% |
Sell
Neutral
Buy
Perrigo Company Public Limited Company is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Perrigo Company Public Limited Company | 0.1% | -0.13% | -17.27% | -27.96% | -38.47% |
Neurocrine Biosciences Inc. | -4.45% | 18.72% | 28.45% | 40.46% | 69.87% |
Haleon Plc Spon Ads | -0.12% | -1.82% | -7.31% | 9.45% | 9.45% |
Zoetis Inc. | -10.98% | -10.38% | -12.9% | -9.61% | 53.43% |
Viatris Inc. | -5.61% | 18.46% | 12.35% | -16.23% | -32.07% |
Catalent, Inc. | 0.0% | 24.33% | 32.98% | -48.49% | 27.27% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Perrigo Company Public Limited Company | 402.13 | NA | 0.96 | 2.35 | 0.0 | 0.02 | 0.04 | 35.19 |
Neurocrine Biosciences Inc. | 53.84 | 53.84 | 0.44 | 4.78 | 0.13 | 0.09 | NA | 22.61 |
Haleon Plc Spon Ads | 28.93 | 28.93 | 1.69 | 0.45 | 0.07 | 0.04 | 0.03 | 1.8 |
Zoetis Inc. | 29.48 | 29.48 | 2.58 | 5.8 | 0.5 | 0.13 | 0.01 | 10.9 |
Viatris Inc. | 222.4 | 222.4 | NA | 2.78 | 0.0 | 0.03 | 0.04 | 17.05 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.48 | -0.3 | -0.01 | NA | 20.41 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Perrigo Company Public Limited Company | Buy | $4.1B | -38.47% | 402.13 | -0.27% |
Neurocrine Biosciences Inc. | Buy | $13.4B | 69.87% | 53.84 | 13.23% |
Haleon Plc Spon Ads | Buy | $37.0B | 9.45% | 28.93 | 9.28% |
Zoetis Inc. | Buy | $68.5B | 53.43% | 29.48 | 27.43% |
Viatris Inc. | Hold | $13.2B | -32.07% | 222.4 | 0.35% |
Catalent, Inc. | Hold | $10.1B | 27.27% | 211.02 | -31.77% |
Vanguard Group Inc
BlackRock Inc
Dimensional Fund Advisors, Inc.
State Street Corporation
Wolf Hill Capital Management, LP
Cooke & Bieler LP
In the quarter ending March,2024. Perrigo Company Public Limited Company has declared dividend of $0.28
Read Moreperrigo company plc, a top five global over-the-counter (otc) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. from its beginnings in 1887 as a packager of generic home remedies, perrigo, headquartered in ireland, has grown to become the world's largest manufacturer of otc products and supplier of infant formulas for the store brand market. the company is also a leading provider of branded otc products, generic extended topical prescription products and receives royalties from multiple sclerosis drug tysabri®. perrigo provides “quality affordable healthcare products®” across a wide variety of product categories and geographies primarily in north america, europe, and australia, as well as other key markets including israel and china. visit perrigo online at (http://www.perrigo.com).
Organization | Perrigo Company Public Limited Company |
Employees | 9140 |
CEO | Mr. Patrick Lockwood-Taylor |
Industry | Health Technology |
Endeavor Group Holdings, Inc.
$29.94
-0.33%
Associated Banc-corp
$29.94
-0.33%
Assetmark Financial Holdings Inc
$29.94
-0.33%
Essential Utilities Inc.
$29.94
-0.33%
Vanguard Ultra Short Bond Et
$29.94
-0.33%
Surgery Partners Inc
$29.94
-0.33%
Sl Green Realty Corp.
$29.94
-0.33%
Janus Henderson Mortgage-backed Securities Etf
$29.94
-0.33%
Goldman Sachs Activebeta Int
$29.94
-0.33%